Global Brucellosis Vaccines research
Global Brucellosis Vaccines research

Brucellosis Vaccines Comprehensive Study by Type (DNA Vaccines, Subunit Vaccines, Vector Vaccines, B. Abortus Recombinant Mutants, Others), Application (Cattle, Sheep, Goats, Pigs, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online, Others), Species (Brucella Suis, Brucella Abortus, Brucella Melitensis, Brucella Canis, Others), End User (Veterinary Hospitals, Veterinary Clinics, Animal Care Centers, Others) Players and Region - Global Market Outlook to 2025

Brucellosis Vaccines Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 230 Pages 220 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Brucellosis Vaccines Market Scope?
Brucellosis vaccines are based on live Brucella abortus strain 19, a laboratory-derived strain attenuated by an unknown process during subculture. Brucellosis vaccines play an essential role in bovine brucellosis eradication or control programs. They have been effectively used worldwide for several years. Increasing brucella infection disease in animals like cattle, sheep, goats, and much other livestock has led to significant growth of the global brucellosis vaccine market in the forecast period.

The Brucellosis Vaccines market study is being classified by Type (DNA Vaccines, Subunit Vaccines, Vector Vaccines, B. Abortus Recombinant Mutants and Others), by Application (Cattle, Sheep, Goats, Pigs and Others) and major geographies with country level break-up.

Research Analyst at AMA predicts that Players from European and United States will contribute to the maximum growth of Global Brucellosis Vaccines market throughout the predicted period.

Merck & Co., Inc. (United States), Boehringer Ingelheim Vetmedica, Inc. (United States), Ceva (France), Bayer AG (Germany), Biogenesis-Bago (Argentina), Heska Corporation (United States), Colorado Serum (United States), Boehringer Ingelheim (Germany), SYVA Laboratorios (Spain) and Lohmann Animal Health (Germany) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Indian Immunologicals Ltd. (India) and Merial Ltd. (France).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Brucellosis Vaccines market by Type, Application and Region.

On the basis of geography, the market of Brucellosis Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

On 23rd September 2020, Technology License Agreement on “Brucella abortus S19Δ per vaccine” between ICAR- Indian Veterinary Research Institute (IVRI) and Hester Biosciences Limited. The vaccine will be of immense help in the National Control Programme on Brucellosis.


Influencing Market Trend
  • Increased Demand for Fish, Eggs, Milk, and Animal Protein

Market Drivers
  • Growing Awareness about Animal Health
  • Government Organizations and Associations are Raising Funding for Research and Development

Opportunities
  • Technological Advancement and Development In Brucellosis Vaccines
  • Rising Expenditure on Health Care of Companion Animals across the Globe

Restraints
  • High-Cost Associated with Brucellosis Vaccines

Challenges
  • Strict Government Regulations Regarding Vaccines


Key Target Audience
Brucellosis Vaccines Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.
Report Objectives / Segmentation Covered
By Type
  • DNA Vaccines
  • Subunit Vaccines
  • Vector Vaccines
  • B. Abortus Recombinant Mutants
  • Others
By Application
  • Cattle
  • Sheep
  • Goats
  • Pigs
  • Others
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online
  • Others

By Species
  • Brucella Suis
  • Brucella Abortus
  • Brucella Melitensis
  • Brucella Canis
  • Others

By End User
  • Veterinary Hospitals
  • Veterinary Clinics
  • Animal Care Centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Awareness about Animal Health
      • 3.2.2. Government Organizations and Associations are Raising Funding for Research and Development
    • 3.3. Market Challenges
      • 3.3.1. Strict Government Regulations Regarding Vaccines
    • 3.4. Market Trends
      • 3.4.1. Increased Demand for Fish, Eggs, Milk, and Animal Protein
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Brucellosis Vaccines, by Type, Application, Distribution Channel, Species, End User and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Brucellosis Vaccines (Value)
      • 5.2.1. Global Brucellosis Vaccines by: Type (Value)
        • 5.2.1.1. DNA Vaccines
        • 5.2.1.2. Subunit Vaccines
        • 5.2.1.3. Vector Vaccines
        • 5.2.1.4. B. Abortus Recombinant Mutants
        • 5.2.1.5. Others
      • 5.2.2. Global Brucellosis Vaccines by: Application (Value)
        • 5.2.2.1. Cattle
        • 5.2.2.2. Sheep
        • 5.2.2.3. Goats
        • 5.2.2.4. Pigs
        • 5.2.2.5. Others
      • 5.2.3. Global Brucellosis Vaccines by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacy
        • 5.2.3.2. Retail Pharmacy
        • 5.2.3.3. Online
        • 5.2.3.4. Others
      • 5.2.4. Global Brucellosis Vaccines by: Species (Value)
        • 5.2.4.1. Brucella Suis
        • 5.2.4.2. Brucella Abortus
        • 5.2.4.3. Brucella Melitensis
        • 5.2.4.4. Brucella Canis
        • 5.2.4.5. Others
      • 5.2.5. Global Brucellosis Vaccines by: End User (Value)
        • 5.2.5.1. Veterinary Hospitals
        • 5.2.5.2. Veterinary Clinics
        • 5.2.5.3. Animal Care Centers
        • 5.2.5.4. Others
      • 5.2.6. Global Brucellosis Vaccines Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Brucellosis Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck & Co., Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Boehringer Ingelheim Vetmedica, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Ceva (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bayer AG (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Biogenesis-Bago (Argentina)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Heska Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Colorado Serum (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Boehringer Ingelheim (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. SYVA Laboratorios (Spain)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Lohmann Animal Health (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Brucellosis Vaccines Sale, by Type, Application, Distribution Channel, Species, End User and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Brucellosis Vaccines (Value)
      • 7.2.1. Global Brucellosis Vaccines by: Type (Value)
        • 7.2.1.1. DNA Vaccines
        • 7.2.1.2. Subunit Vaccines
        • 7.2.1.3. Vector Vaccines
        • 7.2.1.4. B. Abortus Recombinant Mutants
        • 7.2.1.5. Others
      • 7.2.2. Global Brucellosis Vaccines by: Application (Value)
        • 7.2.2.1. Cattle
        • 7.2.2.2. Sheep
        • 7.2.2.3. Goats
        • 7.2.2.4. Pigs
        • 7.2.2.5. Others
      • 7.2.3. Global Brucellosis Vaccines by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacy
        • 7.2.3.2. Retail Pharmacy
        • 7.2.3.3. Online
        • 7.2.3.4. Others
      • 7.2.4. Global Brucellosis Vaccines by: Species (Value)
        • 7.2.4.1. Brucella Suis
        • 7.2.4.2. Brucella Abortus
        • 7.2.4.3. Brucella Melitensis
        • 7.2.4.4. Brucella Canis
        • 7.2.4.5. Others
      • 7.2.5. Global Brucellosis Vaccines by: End User (Value)
        • 7.2.5.1. Veterinary Hospitals
        • 7.2.5.2. Veterinary Clinics
        • 7.2.5.3. Animal Care Centers
        • 7.2.5.4. Others
      • 7.2.6. Global Brucellosis Vaccines Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Brucellosis Vaccines: by Type(USD Million)
  • Table 2. Brucellosis Vaccines DNA Vaccines , by Region USD Million (2014-2019)
  • Table 3. Brucellosis Vaccines Subunit Vaccines , by Region USD Million (2014-2019)
  • Table 4. Brucellosis Vaccines Vector Vaccines , by Region USD Million (2014-2019)
  • Table 5. Brucellosis Vaccines B. Abortus Recombinant Mutants , by Region USD Million (2014-2019)
  • Table 6. Brucellosis Vaccines Others , by Region USD Million (2014-2019)
  • Table 7. Brucellosis Vaccines: by Application(USD Million)
  • Table 8. Brucellosis Vaccines Cattle , by Region USD Million (2014-2019)
  • Table 9. Brucellosis Vaccines Sheep , by Region USD Million (2014-2019)
  • Table 10. Brucellosis Vaccines Goats , by Region USD Million (2014-2019)
  • Table 11. Brucellosis Vaccines Pigs , by Region USD Million (2014-2019)
  • Table 12. Brucellosis Vaccines Others , by Region USD Million (2014-2019)
  • Table 13. Brucellosis Vaccines: by Distribution Channel(USD Million)
  • Table 14. Brucellosis Vaccines Hospital Pharmacy , by Region USD Million (2014-2019)
  • Table 15. Brucellosis Vaccines Retail Pharmacy , by Region USD Million (2014-2019)
  • Table 16. Brucellosis Vaccines Online , by Region USD Million (2014-2019)
  • Table 17. Brucellosis Vaccines Others , by Region USD Million (2014-2019)
  • Table 18. Brucellosis Vaccines: by Species(USD Million)
  • Table 19. Brucellosis Vaccines Brucella Suis , by Region USD Million (2014-2019)
  • Table 20. Brucellosis Vaccines Brucella Abortus , by Region USD Million (2014-2019)
  • Table 21. Brucellosis Vaccines Brucella Melitensis , by Region USD Million (2014-2019)
  • Table 22. Brucellosis Vaccines Brucella Canis , by Region USD Million (2014-2019)
  • Table 23. Brucellosis Vaccines Others , by Region USD Million (2014-2019)
  • Table 24. Brucellosis Vaccines: by End User(USD Million)
  • Table 25. Brucellosis Vaccines Veterinary Hospitals , by Region USD Million (2014-2019)
  • Table 26. Brucellosis Vaccines Veterinary Clinics , by Region USD Million (2014-2019)
  • Table 27. Brucellosis Vaccines Animal Care Centers , by Region USD Million (2014-2019)
  • Table 28. Brucellosis Vaccines Others , by Region USD Million (2014-2019)
  • Table 29. South America Brucellosis Vaccines, by Country USD Million (2014-2019)
  • Table 30. South America Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 31. South America Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 32. South America Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 33. South America Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 34. South America Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 35. Brazil Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 36. Brazil Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 37. Brazil Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 38. Brazil Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 39. Brazil Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 40. Argentina Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 41. Argentina Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 42. Argentina Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 43. Argentina Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 44. Argentina Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 45. Rest of South America Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 46. Rest of South America Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 47. Rest of South America Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 48. Rest of South America Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 49. Rest of South America Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 50. Asia Pacific Brucellosis Vaccines, by Country USD Million (2014-2019)
  • Table 51. Asia Pacific Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 52. Asia Pacific Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 53. Asia Pacific Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 54. Asia Pacific Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 55. Asia Pacific Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 56. China Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 57. China Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 58. China Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 59. China Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 60. China Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 61. Japan Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 62. Japan Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 63. Japan Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 64. Japan Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 65. Japan Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 66. India Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 67. India Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 68. India Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 69. India Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 70. India Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 71. South Korea Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 72. South Korea Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 73. South Korea Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 74. South Korea Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 75. South Korea Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 76. Taiwan Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 77. Taiwan Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 78. Taiwan Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 79. Taiwan Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 80. Taiwan Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 81. Australia Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 82. Australia Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 83. Australia Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 84. Australia Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 85. Australia Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 86. Rest of Asia-Pacific Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 87. Rest of Asia-Pacific Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 88. Rest of Asia-Pacific Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 89. Rest of Asia-Pacific Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 90. Rest of Asia-Pacific Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 91. Europe Brucellosis Vaccines, by Country USD Million (2014-2019)
  • Table 92. Europe Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 93. Europe Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 94. Europe Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 95. Europe Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 96. Europe Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 97. Germany Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 98. Germany Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 99. Germany Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 100. Germany Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 101. Germany Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 102. France Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 103. France Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 104. France Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 105. France Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 106. France Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 107. Italy Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 108. Italy Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 109. Italy Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 110. Italy Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 111. Italy Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 112. United Kingdom Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 113. United Kingdom Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 114. United Kingdom Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 115. United Kingdom Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 116. United Kingdom Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 117. Netherlands Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 118. Netherlands Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 119. Netherlands Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 120. Netherlands Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 121. Netherlands Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 122. Rest of Europe Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 123. Rest of Europe Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 124. Rest of Europe Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 125. Rest of Europe Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 126. Rest of Europe Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 127. MEA Brucellosis Vaccines, by Country USD Million (2014-2019)
  • Table 128. MEA Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 129. MEA Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 130. MEA Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 131. MEA Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 132. MEA Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 133. Middle East Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 134. Middle East Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 135. Middle East Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 136. Middle East Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 137. Middle East Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 138. Africa Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 139. Africa Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 140. Africa Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 141. Africa Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 142. Africa Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 143. North America Brucellosis Vaccines, by Country USD Million (2014-2019)
  • Table 144. North America Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 145. North America Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 146. North America Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 147. North America Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 148. North America Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 149. United States Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 150. United States Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 151. United States Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 152. United States Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 153. United States Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 154. Canada Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 155. Canada Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 156. Canada Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 157. Canada Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 158. Canada Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 159. Mexico Brucellosis Vaccines, by Type USD Million (2014-2019)
  • Table 160. Mexico Brucellosis Vaccines, by Application USD Million (2014-2019)
  • Table 161. Mexico Brucellosis Vaccines, by Distribution Channel USD Million (2014-2019)
  • Table 162. Mexico Brucellosis Vaccines, by Species USD Million (2014-2019)
  • Table 163. Mexico Brucellosis Vaccines, by End User USD Million (2014-2019)
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Company Basic Information, Sales Area and Its Competitors
  • Table 174. Brucellosis Vaccines: by Type(USD Million)
  • Table 175. Brucellosis Vaccines DNA Vaccines , by Region USD Million (2020-2025)
  • Table 176. Brucellosis Vaccines Subunit Vaccines , by Region USD Million (2020-2025)
  • Table 177. Brucellosis Vaccines Vector Vaccines , by Region USD Million (2020-2025)
  • Table 178. Brucellosis Vaccines B. Abortus Recombinant Mutants , by Region USD Million (2020-2025)
  • Table 179. Brucellosis Vaccines Others , by Region USD Million (2020-2025)
  • Table 180. Brucellosis Vaccines: by Application(USD Million)
  • Table 181. Brucellosis Vaccines Cattle , by Region USD Million (2020-2025)
  • Table 182. Brucellosis Vaccines Sheep , by Region USD Million (2020-2025)
  • Table 183. Brucellosis Vaccines Goats , by Region USD Million (2020-2025)
  • Table 184. Brucellosis Vaccines Pigs , by Region USD Million (2020-2025)
  • Table 185. Brucellosis Vaccines Others , by Region USD Million (2020-2025)
  • Table 186. Brucellosis Vaccines: by Distribution Channel(USD Million)
  • Table 187. Brucellosis Vaccines Hospital Pharmacy , by Region USD Million (2020-2025)
  • Table 188. Brucellosis Vaccines Retail Pharmacy , by Region USD Million (2020-2025)
  • Table 189. Brucellosis Vaccines Online , by Region USD Million (2020-2025)
  • Table 190. Brucellosis Vaccines Others , by Region USD Million (2020-2025)
  • Table 191. Brucellosis Vaccines: by Species(USD Million)
  • Table 192. Brucellosis Vaccines Brucella Suis , by Region USD Million (2020-2025)
  • Table 193. Brucellosis Vaccines Brucella Abortus , by Region USD Million (2020-2025)
  • Table 194. Brucellosis Vaccines Brucella Melitensis , by Region USD Million (2020-2025)
  • Table 195. Brucellosis Vaccines Brucella Canis , by Region USD Million (2020-2025)
  • Table 196. Brucellosis Vaccines Others , by Region USD Million (2020-2025)
  • Table 197. Brucellosis Vaccines: by End User(USD Million)
  • Table 198. Brucellosis Vaccines Veterinary Hospitals , by Region USD Million (2020-2025)
  • Table 199. Brucellosis Vaccines Veterinary Clinics , by Region USD Million (2020-2025)
  • Table 200. Brucellosis Vaccines Animal Care Centers , by Region USD Million (2020-2025)
  • Table 201. Brucellosis Vaccines Others , by Region USD Million (2020-2025)
  • Table 202. South America Brucellosis Vaccines, by Country USD Million (2020-2025)
  • Table 203. South America Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 204. South America Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 205. South America Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 206. South America Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 207. South America Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 208. Brazil Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 209. Brazil Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 210. Brazil Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 211. Brazil Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 212. Brazil Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 213. Argentina Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 214. Argentina Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 215. Argentina Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 216. Argentina Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 217. Argentina Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 218. Rest of South America Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 219. Rest of South America Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 220. Rest of South America Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 221. Rest of South America Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 222. Rest of South America Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 223. Asia Pacific Brucellosis Vaccines, by Country USD Million (2020-2025)
  • Table 224. Asia Pacific Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 225. Asia Pacific Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 226. Asia Pacific Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 227. Asia Pacific Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 228. Asia Pacific Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 229. China Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 230. China Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 231. China Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 232. China Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 233. China Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 234. Japan Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 235. Japan Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 236. Japan Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 237. Japan Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 238. Japan Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 239. India Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 240. India Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 241. India Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 242. India Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 243. India Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 244. South Korea Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 245. South Korea Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 246. South Korea Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 247. South Korea Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 248. South Korea Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 249. Taiwan Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 250. Taiwan Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 251. Taiwan Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 252. Taiwan Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 253. Taiwan Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 254. Australia Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 255. Australia Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 256. Australia Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 257. Australia Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 258. Australia Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 259. Rest of Asia-Pacific Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 260. Rest of Asia-Pacific Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 261. Rest of Asia-Pacific Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 262. Rest of Asia-Pacific Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 263. Rest of Asia-Pacific Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 264. Europe Brucellosis Vaccines, by Country USD Million (2020-2025)
  • Table 265. Europe Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 266. Europe Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 267. Europe Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 268. Europe Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 269. Europe Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 270. Germany Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 271. Germany Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 272. Germany Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 273. Germany Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 274. Germany Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 275. France Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 276. France Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 277. France Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 278. France Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 279. France Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 280. Italy Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 281. Italy Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 282. Italy Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 283. Italy Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 284. Italy Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 285. United Kingdom Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 286. United Kingdom Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 287. United Kingdom Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 288. United Kingdom Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 289. United Kingdom Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 290. Netherlands Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 291. Netherlands Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 292. Netherlands Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 293. Netherlands Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 294. Netherlands Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 295. Rest of Europe Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 296. Rest of Europe Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 297. Rest of Europe Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 298. Rest of Europe Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 299. Rest of Europe Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 300. MEA Brucellosis Vaccines, by Country USD Million (2020-2025)
  • Table 301. MEA Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 302. MEA Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 303. MEA Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 304. MEA Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 305. MEA Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 306. Middle East Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 307. Middle East Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 308. Middle East Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 309. Middle East Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 310. Middle East Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 311. Africa Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 312. Africa Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 313. Africa Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 314. Africa Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 315. Africa Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 316. North America Brucellosis Vaccines, by Country USD Million (2020-2025)
  • Table 317. North America Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 318. North America Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 319. North America Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 320. North America Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 321. North America Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 322. United States Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 323. United States Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 324. United States Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 325. United States Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 326. United States Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 327. Canada Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 328. Canada Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 329. Canada Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 330. Canada Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 331. Canada Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 332. Mexico Brucellosis Vaccines, by Type USD Million (2020-2025)
  • Table 333. Mexico Brucellosis Vaccines, by Application USD Million (2020-2025)
  • Table 334. Mexico Brucellosis Vaccines, by Distribution Channel USD Million (2020-2025)
  • Table 335. Mexico Brucellosis Vaccines, by Species USD Million (2020-2025)
  • Table 336. Mexico Brucellosis Vaccines, by End User USD Million (2020-2025)
  • Table 337. Research Programs/Design for This Report
  • Table 338. Key Data Information from Secondary Sources
  • Table 339. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Brucellosis Vaccines: by Type USD Million (2014-2019)
  • Figure 5. Global Brucellosis Vaccines: by Application USD Million (2014-2019)
  • Figure 6. Global Brucellosis Vaccines: by Distribution Channel USD Million (2014-2019)
  • Figure 7. Global Brucellosis Vaccines: by Species USD Million (2014-2019)
  • Figure 8. Global Brucellosis Vaccines: by End User USD Million (2014-2019)
  • Figure 9. South America Brucellosis Vaccines Share (%), by Country
  • Figure 10. Asia Pacific Brucellosis Vaccines Share (%), by Country
  • Figure 11. Europe Brucellosis Vaccines Share (%), by Country
  • Figure 12. MEA Brucellosis Vaccines Share (%), by Country
  • Figure 13. North America Brucellosis Vaccines Share (%), by Country
  • Figure 14. Global Brucellosis Vaccines share by Players 2019 (%)
  • Figure 15. Global Brucellosis Vaccines share by Players (Top 3) 2019(%)
  • Figure 16. Global Brucellosis Vaccines share by Players (Top 5) 2019(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Merck & Co., Inc. (United States) Revenue: by Geography 2019
  • Figure 20. Boehringer Ingelheim Vetmedica, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Boehringer Ingelheim Vetmedica, Inc. (United States) Revenue: by Geography 2019
  • Figure 22. Ceva (France) Revenue, Net Income and Gross profit
  • Figure 23. Ceva (France) Revenue: by Geography 2019
  • Figure 24. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Bayer AG (Germany) Revenue: by Geography 2019
  • Figure 26. Biogenesis-Bago (Argentina) Revenue, Net Income and Gross profit
  • Figure 27. Biogenesis-Bago (Argentina) Revenue: by Geography 2019
  • Figure 28. Heska Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 29. Heska Corporation (United States) Revenue: by Geography 2019
  • Figure 30. Colorado Serum (United States) Revenue, Net Income and Gross profit
  • Figure 31. Colorado Serum (United States) Revenue: by Geography 2019
  • Figure 32. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 33. Boehringer Ingelheim (Germany) Revenue: by Geography 2019
  • Figure 34. SYVA Laboratorios (Spain) Revenue, Net Income and Gross profit
  • Figure 35. SYVA Laboratorios (Spain) Revenue: by Geography 2019
  • Figure 36. Lohmann Animal Health (Germany) Revenue, Net Income and Gross profit
  • Figure 37. Lohmann Animal Health (Germany) Revenue: by Geography 2019
  • Figure 38. Global Brucellosis Vaccines: by Type USD Million (2020-2025)
  • Figure 39. Global Brucellosis Vaccines: by Application USD Million (2020-2025)
  • Figure 40. Global Brucellosis Vaccines: by Distribution Channel USD Million (2020-2025)
  • Figure 41. Global Brucellosis Vaccines: by Species USD Million (2020-2025)
  • Figure 42. Global Brucellosis Vaccines: by End User USD Million (2020-2025)
  • Figure 43. South America Brucellosis Vaccines Share (%), by Country
  • Figure 44. Asia Pacific Brucellosis Vaccines Share (%), by Country
  • Figure 45. Europe Brucellosis Vaccines Share (%), by Country
  • Figure 46. MEA Brucellosis Vaccines Share (%), by Country
  • Figure 47. North America Brucellosis Vaccines Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Merck & Co., Inc. (United States)
  • Boehringer Ingelheim Vetmedica, Inc. (United States)
  • Ceva (France)
  • Bayer AG (Germany)
  • Biogenesis-Bago (Argentina)
  • Heska Corporation (United States)
  • Colorado Serum (United States)
  • Boehringer Ingelheim (Germany)
  • SYVA Laboratorios (Spain)
  • Lohmann Animal Health (Germany)
Additional players considered in the study are as follows:
Indian Immunologicals Ltd. (India) , Merial Ltd. (France)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation